- Home
- HIND vs NRXS Comparison
HIND vs NRXS Comparison
Compare HIND & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HIND | NRXS |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.0M | 25.8M |
| IPO Year | 2016 | 2023 |
Fundamental Metrics
Financial Performance| Metric | HIND | NRXS |
|---|---|---|
| Price | $4.85 | $2.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | N/A | ★ 55.5K |
| Earning Date | N/A | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | N/A | $1.33 |
| 52 Week High | N/A | $6.20 |
Technical Indicators
Market Signals| Indicator | HIND | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 43.92 | 52.53 |
| Support Level | $4.80 | $2.54 |
| Resistance Level | $5.88 | $2.82 |
| Average True Range (ATR) | 0.43 | 0.18 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 30.56 | 87.11 |
Price Performance
Historical ComparisonAbout HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).